Viewing Study NCT03932318

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 5:00 AM
Ignite Modification Date: 2026-02-28 @ 5:29 AM
Study NCT ID: NCT03932318
Status: WITHDRAWN
Last Update Posted: 2023-07-20
First Post: 2019-04-17
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
Sponsor: Actinium Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Myeloid Leukemia View
None Relapsed Adult AML View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Lintuzumab-Ac225 View
None Venetoclax View
None Azacitidine View
None Lintuzumab View
None Refractory AML View